Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 208-216

  Miura, M ^a   Niioka, T ^b   Kagaya, H ^a   Saito, M ^c   Hayakari, M ^b   Habuchi, T ^c   Satoh, S ^c  

^a Hirosaki University Hospital ^*

^b HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^c AKITA UNIVERSITY   (Japan)

Author keywords

CYP2C19; CYP3A5; drug interaction; Lansoprazole; Pharmacogenetics; Polymorphism; Rabeprazole; Tacrolimus

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; LANSOPRAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PATIENT MONITORING; PHARMACOGENETICS; POSTOPERATIVE PERIOD;

EID: 79952276081     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01163.x     Document Type: Article

References (44)

1. Staatz CE, Tett SE, (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical Pharmacokinetics, 43, 623-653. (Pubitemid 38981845)
2. Hesselink DA, van Schaik RH, van der Heiden IP, et al., (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics, 74, 245-254. (Pubitemid 37083100)
3. Roy JN, Barama A, Poirier C, Vinet B, Roger M, (2006) Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenetics and Genomics, 16, 659-665. (Pubitemid 44223077)
4. Hesselink DA, van Gelder T, van Schaik RH., (2005) The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics, 6, 323-337. (Pubitemid 40916357)
5. Nagaya H, Satoh H, Maki Y, (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. The Journal of Pharmacology and Experimental Therapeutics, 252, 1289-1295. (Pubitemid 20127442)
6. Morii M, Takata H, Fujisaki H, Takeguchi N, (1990) The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochemical Pharmacology, 39, 661-667. (Pubitemid 20055759)
7. Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N, (1991) Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochemical Pharmacology, 42, 321-328.
8. Prakash A, Faulds D, (1998) Rabeprazole. Drugs, 55, 261-267.
9. Troppmann C, Papalois BE, Chiou A, et al., (1995) Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine. Journal of the American College of Surgeons, 180, 433-443.
10. Chen KJ, Chen CH, Cheng CH, et al., (2004) Risk factors for peptic ulcer disease in renal transplant patient-11 years of experience from a single center. Clinical Nephrology, 62, 14-20.
11. Suwelack B, Gabriels G, Volmer S, Hillebrand U, Hohage H, Pohle T, (2005) Resolution of severe MMF-related gastrointestinal adverse events following conversion to enteric-coated mycophenolate sodium. Transplantation, 79, 987-988. (Pubitemid 40586878)
12. Altomare JF, Smith RE, Potdar S, Mitchell SH, (2006) Delayed gastric ulcer healing associated with sirolimus. Transplantation, 82, 437-438. (Pubitemid 44223047)
13. Miura M, Inoue K, Kagaya H, et al., (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharmaceutics and Drug Disposition, 28, 167-175. (Pubitemid 46824853)
14. Hosohata K, Masuda S, Ogura Y, et al., (2008) Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metabolism and Pharmacokinetics, 23, 134-138.
15. Itagaki F, Homma M, Yuzawa K, et al., (2004) Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. The Journal of Pharmacy and Pharmacology, 56, 1055-1059. (Pubitemid 39140062)
16. Takahashi K, Motohashi H, Yonezawa A, et al., (2004) Lansoprazole- tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. The Annals of Pharmacotherapy, 38, 791-794. (Pubitemid 38509054)
17. Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y, (2002) Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation, 73, 303-304. (Pubitemid 34112860)
18. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A, (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. The Journal of Pharmacology and Experimental Therapeutics, 277, 805-816. (Pubitemid 27168992)
19. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M, (1997) Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. European Journal of Clinical Pharmacology, 52, 391-396. (Pubitemid 27341941)
20. Pichard L, Curi-Pedrosa R, Bonfils C, et al., (1995) Oxidative metabolism of lansoprazole by human liver cytochromes P450. Molecular Pharmacology, 47, 410-418.
21. Miura M, Tada H, Suzuki T, (2004) Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 804, 389-395. (Pubitemid 38481715)
22. Miura M, Tada H, Satoh S, Habuchi T, Suzuki T, (2006) Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction. Journal of Pharmaceutical and Biomedical Analysis, 41, 565-570.
23. Miura M, Kagaya H, Tada H, et al., (2005) Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica, 35, 479-486. (Pubitemid 41044392)
24. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J, (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population. Pharmacogenetics, 12, 331-334. (Pubitemid 34620661)
25. Ruzilawati AB, Suhaimi AW, Gan SH, (2007) Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clinica Chimica Acta, 383, 158-162. (Pubitemid 47016453)
26. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M, (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology and Therapeutics, 79, 103-113. (Pubitemid 43069582)
27. Itoh K, Inoue K, Yanagiwara S, Kyoya H, Suzuki T, (1999) Rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Biological and Pharmaceutical Bulletin, 22, 7-9.
28. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K, (2007) Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. British Journal of Clinical Pharmacology, 64, 185-191. (Pubitemid 47063248)
29. Tada H, Tsuchiya N, Satoh S, et al., (2005) Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation Proceedings, 37, 1730-1732. (Pubitemid 40790812)
30. Kagaya H, Miura M, Satoh S, et al., (2008) No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. Journal of Clinical Pharmacy and Therapeutics, 33, 193-201. (Pubitemid 351341413)
31. Hsieh KP, Lin YY, Cheng CL, et al., (2001) Novel mutations of CYP3A4 in Chinese. Drug Metabolism and Disposition, 29, 268-273.
32. Lamba JK, Lin YS, Thummel K, et al., (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics, 12, 121-132. (Pubitemid 34298916)
33. *18 single nucleotide polymorphisms in a Chinese population. Clinica Chimica Acta, 253, 187-192. (Pubitemid 40215445)
34. Dai D, Tang J, Rose R, Hodgson E, Bienstock RL, Mohrenweiser HW, (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. The Journal of Pharmacology and Experimental Therapeutics, 299, 825-831. (Pubitemid 33104948)
35. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Suzuki T, Habuchi T, (2008) Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Therapeutic Drug Monitoring, 30, 46-51. (Pubitemid 351161098)
36. Christians U, Jacobsen W, Benet LZ, Lampen A, (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clinical Pharmacokinetics, 41, 813-851.
37. David OJ, Johnston A, (2001) Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Therapeutic Drug Monitoring, 23, 100-114. (Pubitemid 32240136)
38. Bertilsson L, Lou YQ, Du YL, et al., (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clinical Pharmacology and Therapeutics, 51, 388-397.
39. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA, (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clinical Pharmacology and Therapeutics, 36, 773-780. (Pubitemid 15243796)
40. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA, (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7, 59-64. (Pubitemid 27153320)
41. Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, Flockhart DA, (1996) Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clinical Pharmacology and Therapeutics, 60, 138-144. (Pubitemid 26348228)
42. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L, (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 6, 547-551.
43. Kimura M, Ieiri I, Wada Y, et al., (1999) Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. British Journal of Clinical Pharmacology, 47, 115-119. (Pubitemid 29043174)
44. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA, (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics, 38, 402-408. (Pubitemid 16250313)